ADME toxicology testing market to reach $20.25 billion by 2030

The ADME toxicology testing market is projected to grow from $11.5 billion in 2025 to $20.25 billion by 2030, driven by rising drug development activity, tighter safety rules and broader use of advanced testing tools. North America leads now, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - ADME toxicology testing helps drug makers assess how a compound is absorbed, distributed, metabolized and excreted before it reaches patients. - The market’s growth reflects rising pressure to prove drug safety earlier in development. - Demand is also expanding beyond pharmaceuticals into cosmetics and food testing.

What happened: - The Business Research Company released its ADME Toxicology Testing Global Market Report 2026 – Market Size, Trends, and Forecast 2026-2035. - The report estimates the market at $11.5 billion in 2025 and $12.83 billion in 2026. - The market is forecast to reach $20.25 billion by 2030, representing a 12.1% CAGR through the period. - North America held the largest market share in 2025. - Asia-Pacific is projected to post the fastest growth during the forecast period. - The report covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample and the full report are available online.

The details: - The report says recent growth has been supported by limited adoption of automated ADME testing systems, dependence on traditional biochemical assays and higher regulatory scrutiny of drug safety. - Expanding pharmaceutical research and increased use of LC-MS and HPLC instruments also contributed to growth. - Future growth drivers include integrated ADME testing platforms, omics and molecular imaging techniques, predictive toxicology software and AI-enabled risk assessment tools. - The report also points to broader use of cell-based and in vitro assays, high-throughput screening instruments and simulation and modeling software. - ADME testing is used to identify harmful metabolites and toxicities early in the drug development process. - Rising demand for novel drugs is a major driver. - The FDA’s Center for Drug Evaluation and Research reported 55 novel drug approvals in 2023, including 20 first-in-class agents, up from 37 approvals in 2022. - Pharmaceutical production in Europe rose from €363.3 billion in 2022 to €390 billion in 2023, according to EFPIA data cited in the report.

Between the lines: - The market is being pulled by two forces at once: more drug candidates are entering development, and regulators are demanding stronger safety evidence. - Technology is shifting the testing mix toward faster, more data-rich methods. - The report’s forecast suggests ADME toxicology is becoming a larger, more specialized part of the drug development workflow.

What's next: - The report expects continued adoption of automated, integrated and AI-supported testing tools. - Asia-Pacific growth is likely to stay strong as pharmaceutical research investment rises and advanced testing technologies spread. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, market hotspot infographics and updated trend graphics.

The bottom line: - ADME toxicology testing is moving from a supporting lab function to a bigger strategic market as drug pipelines, regulation and predictive technology all expand at once.